414 related articles for article (PubMed ID: 22434305)
21. Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series.
Bögl HP; Aspenberg P; Schilcher J
Osteoporos Int; 2017 Aug; 28(8):2439-2444. PubMed ID: 28474166
[TBL] [Abstract][Full Text] [Related]
22. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
23. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
[TBL] [Abstract][Full Text] [Related]
24. Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed!
Rydholm A
Acta Orthop; 2012 Aug; 83(4):319-20. PubMed ID: 22900912
[No Abstract] [Full Text] [Related]
25. Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy.
Lim HS; Kim CK; Park YS; Moon YW; Lim SJ; Kim SM
J Bone Joint Surg Am; 2016 Dec; 98(23):1978-1987. PubMed ID: 27926679
[TBL] [Abstract][Full Text] [Related]
26. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
27. Atypical forearm fractures associated with long-term use of bisphosphonate.
Moon J; Bither N; Lee T
Arch Orthop Trauma Surg; 2013 Jul; 133(7):889-92. PubMed ID: 23619919
[TBL] [Abstract][Full Text] [Related]
28. Atypical bilateral femoral shaft fracture in patient treated with bisphosphonates.
Parrón Cambero R; Rey López A; Tomé-Bermejo F; Cibantos Martínez R
Eur J Orthop Surg Traumatol; 2013 Nov; 23 Suppl 2():S219-23. PubMed ID: 23412218
[TBL] [Abstract][Full Text] [Related]
29. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.
Patel VC; Lazzarini AM
Orthopedics; 2010 Oct; 33(10):775. PubMed ID: 20954650
[TBL] [Abstract][Full Text] [Related]
30. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
31. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
32. ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOSPHONATES THERAPY: CASE REPORT.
Găleşanu C; Mocanu V; Buzdugă C; Florescu A; Zaharia V; Lisnic V
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):114-8. PubMed ID: 27125082
[TBL] [Abstract][Full Text] [Related]
33. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
34. Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
Wang K; Moaveni A; Dowrick A; Liew S
J Orthop Surg (Hong Kong); 2011 Apr; 19(1):89-92. PubMed ID: 21519086
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
36. Surgical Complications Associated With Atypical Femur Fractures Attributed to Bisphosphonate Use.
Schultz DS; Gass HM; Barfield WR; Demos HA; Hartsock LA
J Surg Orthop Adv; 2018; 27(1):14-20. PubMed ID: 29762110
[TBL] [Abstract][Full Text] [Related]
37. A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid.
Ishizuna K; Ota D; Fukuuchi A; Teraoka M; Fujii A; Mori M; Nishi T
Breast Cancer; 2015 Jan; 22(1):90-4. PubMed ID: 22009549
[TBL] [Abstract][Full Text] [Related]
38. Can long-term bisphosphonate use causes low-energy fractures? A case report.
Dandinoğlu T; Akarsu S; Karadeniz M; Tekin L; Arıbal S; Kıralp MZ
Osteoporos Int; 2014 Feb; 25(2):773-6. PubMed ID: 23824297
[TBL] [Abstract][Full Text] [Related]
39. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
